U.S. Markets close in 31 mins

Introducing Innate Pharma (EPA:IPH), The Stock That Slid 62% In The Last Three Years

Simply Wall St

If you love investing in stocks you're bound to buy some losers. But the long term shareholders of Innate Pharma S.A. (EPA:IPH) have had an unfortunate run in the last three years. So they might be feeling emotional about the 62% share price collapse, in that time. And more recent buyers are having a tough time too, with a drop of 29% in the last year. There was little comfort for shareholders in the last week as the price declined a further 4.8%.

View our latest analysis for Innate Pharma

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

During five years of share price growth, Innate Pharma moved from a loss to profitability. We would usually expect to see the share price rise as a result. So it's worth looking at other metrics to try to understand the share price move.

We note that, in three years, revenue has actually grown at a 29% annual rate, so that doesn't seem to be a reason to sell shares. It's probably worth investigating Innate Pharma further; while we may be missing something on this analysis, there might also be an opportunity.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

ENXTPA:IPH Income Statement, November 18th 2019

We know that Innate Pharma has improved its bottom line lately, but what does the future have in store? If you are thinking of buying or selling Innate Pharma stock, you should check out this free report showing analyst profit forecasts.

A Different Perspective

While the broader market gained around 21% in the last year, Innate Pharma shareholders lost 29%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 6.6% per year over five years. We realise that Buffett has said investors should 'buy when there is blood on the streets', but we caution that investors should first be sure they are buying a high quality businesses. Before deciding if you like the current share price, check how Innate Pharma scores on these 3 valuation metrics.

We will like Innate Pharma better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on FR exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.